Follow-up of colorectal cancer and patterns of recurrence

Haria, Purvi; Baheti, Akshay D.; Palsetia, Delnaz; Ankathi, Suman Kumar; Choudhari, Amit; Guha, Amrita; Saklani, Avanish; Sinha, Rakesh

doi:10.1016/j.crad.2021.07.016

Cited by 17 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, in most CRC cases, the disease is already in its intermediate or advanced stages at diagnosis, rendering surgery an imprudent measure. Even when surgery is performed, the rates of relapse and metastasis for the tumor remain high (Haria et al, 2021; Xu et al, 2020). Consequently, the combination of surgery and adjuvant chemotherapy is now accepted as the standard treatment for CRC (Gelibter et al, 2019; Papamichael et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species‐mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin‐resistant colorectal cancer cells

Zhang

Shen

Zhou

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

Oxaliplatin (OXA) has been recognized as a third-generation platinum-based chemotherapeutic agent with stellar therapeutic efficacy in managing colorectal cancer (CRC). Nevertheless, resistance to OXA in CRC patients hinders its effectiveness. Shikonin (SHI), a natural naphthoquinone derived from Arnebia euchroma (Royle) Johnst., features a broad pharmacological profile and minimal toxicities. To assess the synergism of SHI and OXA towards OXA-resistant CRC cells (HCT116 R ), we employed in vitro and in vivo pharmacological assays. Our experiments provided evidence that SHI, either alone or in combination with OXA, considerably reduced cell proliferation, triggered apoptosis, and induced the generation of reactive oxygen species (ROS) in HCT116 R cells. Furthermore, the combination of SHI and OXA dramatically curbed the extent of HCT116 Rinitiated xenograft growth in mouse models. Bioinformatics, western blot, and ROS assays highlighted that the mechanisms of SHI against OXA-resistant CRC cells may involve the induction of cellular responses to chemical stress, intrinsic apoptosis, as well as endoplasmic reticulum stress pathways mediated by ROS.Notably, the synergism of SHI+OXA was partially abrogated by an ROS inhibitor N-acetyl cysteine. Our findings imply the potential of SHI to boost the sensitivity of OXA to CRC, offering promising benefits for clinical strategies to combat OXA resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species‐mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin‐resistant colorectal cancer cells

Zhang

Shen

Zhou

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…Colon cancer is more likely to appear as the first primary cancer in the combination of synchronous cancer and metachronous cancer. Since the majority of tumors occur in the digestive system, regular follow-up of the lungs should be performed 6 mo after the discovery of colon, rectal, or gastric cancer, and the rectum should be followed up and screened within 6 mo to prevent the occurrence of the second colorectal cancer[ 18 - 20 ].…”

Section: Discussionmentioning

confidence: 99%

High incidence combination of multiple primary malignant tumors of the digestive system

Yang¹,

Zhang²,

Xue³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

BACKGROUND Clinical reports of multiple primary malignant tumors (MPMTs) in the digestive system are increasing. In China, although the survival rate of patients with MPMTs is increasing, the quality of life is very low. Many patients have reached the advanced stage when the second primary tumor is found, resulting in no early intervention and treatment. This is due to the misunderstanding of MPMTs by clinicians, who treat such tumors as metastases. Therefore, before a patient has a second primary tumor, doctors should understand some common combinations of digestive system MPMTs to provide clinical guidance to the patient. AIM To explore the high incidence combination of digestive system MPMTs under heterochronism and synchronization. METHODS A total of 1902 patients with MPMTs at Peking Union Medical College Hospital were analyzed retrospectively. They were divided into metachronous MPMT and synchronous MPMT groups, and then the high incidence combinations of the first primary cancer and the second primary cancer in metachronous cancer and synchronous cancer were sorted. Sex and age differences between metachronous and synchronous tumors were tested by the chi square test and t test, respectively. A P value < 0.05 was considered as statistically significant, and SPSS version 26.0 (SPSS Inc., Chicago, Illinois, United States) was used for statistical analysis. RESULTS Among the 1902 patients with MPMTs confirmed by pathology, 1811 (95.2%) cases were secondary primary cancers, 89 (4.7%) cases were tertiary primary cancers, and 2 (0.1%) cases were quaternary primary cancers. Most (88.2%) of the secondary primary cancers were identified as metachronous multiple primary cancers six months after diagnosis of the first primary cancer. The top ten most common MPMTs in the first primary cancer group ranged from high to low as follows: Breast cancer, thyroid cancer, nonuterine cancer, lung cancer, colon cancer, kidney cancer, uterine cancer, bladder cancer, rectal cancer, and gastric cancer. The highest incidence rate of the first primary cancer in male metachronous cancer was lung cancer (11.6%), the highest incidence rate of the second primary cancer was still lung cancer (24.9%), the highest incidence rate of the first primary cancer in female metachronous cancer was breast cancer (32.7%), and the highest incidence rate of the second primary cancer was lung cancer (20.8%). Among them, breast cancer, nonuterine cancer and uterine cancer were female-specific malignant tumor types, and thyroid cancer also accounted for 79.6% of female patients. The top five metachronous cancer combinations, independent of female-specific malignant tumor types and thyroid cancer, were colon cancer and lung cancer (26 cases), kidney cancer and lung cancer (25 cases), rectal cancer and lung cancer (20 cases), gastric cancer and lung cancer (17 cases), and bladder cancer and lung cance...

show abstract

“…For diagnosed malignant tumors, monitoring disease progression, recurrence and metastasis, and timely treatment are essential to improve the overall survival of patients ( 11 , 12 ). Currently, the commonly used monitoring methods for malignant tumors are high-resolution computed tomography or magnetic resonance imaging combined with conventional tumor biomarkers ( 13 – 15 ).…”

Section: Introductionmentioning

confidence: 99%

Tumor abnormal protein as a promising biomarker for screening solid malignancies and monitoring recurrence and metastasis

Zhang,

Tian,

Liu

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundTumor abnormal protein (TAP), the sugar chain protein released by tumor cells during metabolism, allows the development of a technique that exploits aggregated tumor-associated abnormal sugar chain signals in diagnosing malignancies. Clinically, we have found that TAP detection can well predict some malignancies, but several physicians have not paid attention, and related studies have been minimal.MethodsWe evaluated TAP’s ability to distinguish between malignancies and benign diseases by receiver operating characteristic (ROC) curve analysis and studied the possibility of monitoring malignancy progression by evaluating TAP levels in follow-up. We used Kaplan-Meier survival curves and Cox proportional hazard regression models to investigate the relationship between TAP and prognosis.ResultsTAP levels were higher in whole solid malignancies and every type of solid malignancy than in benign patients. ROC curve analysis showed that TAP levels aid in distinguishing between malignancies and benign diseases. TAP levels decreased in patients with complete remission (CR) after treatment and increased in patients with relapse from CR. Patients with metastases had higher TAP levels than non-CR patients without metastases. There was no difference in overall survival among patients with different TAP levels, and multivariate analysis suggested that TAP was not an independent risk factor for solid malignancies.ConclusionTAP is an effective screening biomarker for many solid malignancies that can be used to monitor the progression of malignancies but not to prognosticate.

show abstract

Follow-up of colorectal cancer and patterns of recurrence

Cited by 17 publications

References 45 publications

Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species‐mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin‐resistant colorectal cancer cells

Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species‐mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin‐resistant colorectal cancer cells

High incidence combination of multiple primary malignant tumors of the digestive system

Tumor abnormal protein as a promising biomarker for screening solid malignancies and monitoring recurrence and metastasis

Contact Info

Product

Resources

About